Frank R. Brennan

Slough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.

Journal: mAbs
Published: July 08, 2025

FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient Safety.

FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient Safety.

Journal: Regulatory toxicology and pharmacology : RTP
Published: April 28, 2025

FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety.

FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety.

Journal: Regulatory toxicology and pharmacology : RTP
Published: April 28, 2025

Assessing the impact and risk of immunomodulatory compounds on pregnancy.

Assessing the impact and risk of immunomodulatory compounds on pregnancy.

Journal: Journal of reproductive immunology
Published: October 16, 2024

Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).

Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).

Journal: Clinical pharmacology and therapeutics
Published: January 31, 2024

Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics.

Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics.

Journal: Drug discovery today
Published: June 23, 2022

Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.

Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.

Journal: Clinical pharmacology and therapeutics
Published: May 04, 2020

Integration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development Paradigms.

Integration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development Paradigms.

Journal: International journal of toxicology
Published: June 22, 2019

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.

Journal: mAbs
Published: August 22, 2018

Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.

Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.

Journal: International immunopharmacology
Published: July 12, 2018

Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.

Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.

Journal: Regulatory toxicology and pharmacology : RTP
Published: June 02, 2018

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Journal: Communications biology
Published: January 03, 2018
Showing 1-12 of 22

Last Updated: 09/26/2026